Alza and Theratechnologies combine products:
This article was originally published in Clinica
Executive Summary
Alza and Theratechnologies are to develop a new product incorporating Alza's Macroflux transdermal drug delivery technology with Theratechnologies' growth hormone-releasing factor analogue (ThGRF). The Macroflux system incorporates a titanium microprojection array that creates superficial pathways through the skin barrier to allow for the transportation of therapeutic proteins and vaccines, says Theratechnologies, of Saint-Laurent, Quebec. ThGRF is being assessed as a treatment for muscle wasting and for sleep disorders.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.